Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies

US10640535B2 · kind B2 · utility

Assignees

• Agenus Inc. · US
• The Board of Regents of the University of Oklahoma · US

Inventors

• Donald F. Hunt · Charlottesville, US
• Andrew Norris · Los Angeles, US
• Ann M. English · Andover, US
• Jeffrey Shabanowitz · Charlottesville, US
• William H. Hilderbrand · Edmond, US
• Oriana E. Hawkins · Fort Worth, US

Key dates

• Filing date: May 28, 2013
• Grant date: May 5, 2020
• Expiry date: Aug 25, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.